Ibere Pharmaceuticals Overview
Ibere Pharmaceuticals (IBER) has a P/E ratio of 29.94, below the sector sector average of 37.35.
Get informed when a big investor buys or sells
+ Follow29.94
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for IBER is 29.94. That is below the sector sector average of 37.35. Investors often review this figure alongside Ibere Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, IBER currently prints 29.94 for P/E ratio, while the sector average sits near 37.35. That is roughly 19.8% below the sector mean. Large gaps often invite a closer look at Ibere Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of 29.94 for Ibere Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (37.35) and with IBER's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting IBER's P/E ratio (29.94), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
